Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Albrecht Neesse

Showing results (61-70 of 111) with videos related to

Pageof 12
Sort By:
Biomed Research International|May 5, 2022
Systematic Retesting for <i>Helicobacter pylori</i>: The Potential Overestimation of Suppressive ConditionsRichard F Knoop, Pauline C Gaertner, Golo Petzold, et al.
Neoplasia (New York, N.Y.)|August 7, 2010
Glutamate receptor GRIA3--target of CUX1 and mediator of tumor progression in pancreatic cancerStefanie Ripka, Jan Riedel, Albrecht Neesse, et al.
Neoplasia (New York, N.Y.)|May 14, 2024
Expression of gemcitabine metabolizing enzymes and stromal components reveal complexities of preclinical pancreatic cancer models for therapeutic testingLisa Knoll, Jacob Hamm, Philipp Stroebel, et al.
European Journal of Gastroenterology & Hepatology|January 11, 2020
Noninvasive assessment of liver fibrosis in a real-world cohort of patients with known or suspected chronic liver disease using 2D-shear wave elastographyGolo Petzold, Sebastian C B Bremer, Richard F Knoop, et al.
Scandinavian Journal of Gastroenterology|March 19, 2019
Evaluation of liver stiffness by 2D-SWE in combination with non-invasive parameters as predictors for esophageal varices in patients with advanced chronic liver diseaseGolo Petzold, Birgit Tsaknakis, Sebastian C B Bremer, et al.
Nature Communications|June 30, 2021
Suppression of HSF1 activity by wildtype p53 creates a driving force for p53 loss-of-heterozygosityTamara Isermann, Özge Çiçek Şener, Adrian Stender, et al.
United European Gastroenterology Journal|June 14, 2022
Activity of acute pancreatitis is modified by secreted protein acidic and rich in cysteine ablationChristoph Ammer-Herrmenau, Laurin Wolf, Syeda S Nasrin, et al.
Plos One|July 11, 2013
Anti-tumour efficacy of capecitabine in a genetically engineered mouse model of pancreatic cancerAurélie Courtin, Frances M Richards, Tashinga E Bapiro, et al.
Cells|December 24, 2021
Chromatin-Independent Interplay of NFATc1 and EZH2 in Pancreatic CancerShilpa Patil, Teresa Forster, Kristina Reutlinger, et al.
Gut|September 27, 2013
SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered miceAlbrecht Neesse, Kristopher K Frese, Derek S Chan, et al.
Pageof 12

Showing results (61-70 of 111) with videos related to

Sort By:
Pageof 12
Biomed Research International|May 5, 2022
Systematic Retesting for <i>Helicobacter pylori</i>: The Potential Overestimation of Suppressive ConditionsRichard F Knoop, Pauline C Gaertner, Golo Petzold, et al.
Neoplasia (New York, N.Y.)|August 7, 2010
Glutamate receptor GRIA3--target of CUX1 and mediator of tumor progression in pancreatic cancerStefanie Ripka, Jan Riedel, Albrecht Neesse, et al.
Neoplasia (New York, N.Y.)|May 14, 2024
Expression of gemcitabine metabolizing enzymes and stromal components reveal complexities of preclinical pancreatic cancer models for therapeutic testingLisa Knoll, Jacob Hamm, Philipp Stroebel, et al.
European Journal of Gastroenterology & Hepatology|January 11, 2020
Noninvasive assessment of liver fibrosis in a real-world cohort of patients with known or suspected chronic liver disease using 2D-shear wave elastographyGolo Petzold, Sebastian C B Bremer, Richard F Knoop, et al.
Scandinavian Journal of Gastroenterology|March 19, 2019
Evaluation of liver stiffness by 2D-SWE in combination with non-invasive parameters as predictors for esophageal varices in patients with advanced chronic liver diseaseGolo Petzold, Birgit Tsaknakis, Sebastian C B Bremer, et al.
Nature Communications|June 30, 2021
Suppression of HSF1 activity by wildtype p53 creates a driving force for p53 loss-of-heterozygosityTamara Isermann, Özge Çiçek Şener, Adrian Stender, et al.
United European Gastroenterology Journal|June 14, 2022
Activity of acute pancreatitis is modified by secreted protein acidic and rich in cysteine ablationChristoph Ammer-Herrmenau, Laurin Wolf, Syeda S Nasrin, et al.
Plos One|July 11, 2013
Anti-tumour efficacy of capecitabine in a genetically engineered mouse model of pancreatic cancerAurélie Courtin, Frances M Richards, Tashinga E Bapiro, et al.
Cells|December 24, 2021
Chromatin-Independent Interplay of NFATc1 and EZH2 in Pancreatic CancerShilpa Patil, Teresa Forster, Kristina Reutlinger, et al.
Gut|September 27, 2013
SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered miceAlbrecht Neesse, Kristopher K Frese, Derek S Chan, et al.
Pageof 12